Innovation of novel therapeutic approach to pancreatic cancer using galectin-3 and AMF

半乳糖凝集素-3(Galectin-3，Gal-3)是一种β-半乳糖苷结合蛋白，能与细胞表面的糖蛋白和糖脂结合。Gal-3参与细胞分化、器官形成、肿瘤进展、细胞凋亡等过程，但其确切机制尚不清楚。本研究利用胰腺癌细胞系研究了Gal-3与胰腺癌的关系，特别是对细胞增殖、迁移和侵袭的影响。我们还分析了当Gal-3在细胞系中的表达水平被抑制时，对抗癌药物耐受性的变化。抑制Gal-3的表达可抑制细胞的迁移和侵袭。它还增加了他们对抗癌药物的敏感性，如吉西他滨和顺铂。

Galectin-3 (Gal-3) is beta-galactoside-binding protein, having binding capacity with glycoprotein and glycolipid on a cell surface. Gal-3 engages in cell differentiation, organ formation, tumor progression, apoptosis and so on, however, precise mechanisms of them have not yet been clarified.We investigated the relationship between Gal-3 and pancreatic cancer, especially on cell proliferation, migration and invasion using pancreatic cancer cell lines. We also analyzed changes of tolerance toward anti-cancer drugs when expression level of Gal-3 was inhibited in the cell lines. Inhibition of Gal-3 expression led to inhibition of migration and invasion of the cells. It also augmented their susceptibility to anti-cancer agents, like gemcitabine and cisplatinum.